Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Clonal Dynamics of Leukemic and Clonal Hematopoiesis Mutations Predict Relapse in Single Cell MRD Analysis of AML in First Complete Remission

Blood (2024) 144 (Supplement 1): 4337.

https://doi.org/10.1182/blood-2024-209953

Published: 2024

Journal Articles

Motixafortide (CXCR4 Inhibition) Alone and in Combination with Natalizumab (VLA-4 Inhibition) As a Novel Regimen to Mobilize Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease: A First-in-Human, Proof-of-Principle Safety and Feasibility Study

Zachary D. Crees, Michael P. Rettig, Reyka G. Jayasinghe, Stephanie Christ, Feng Gao, Hailey Sappington, Sana Saif Ur Rehman, Suzanne R. Thibodeaux, Ella Sorani, Allison A. King, John F. DiPersio

Blood (2024) 144 (Supplement 1): 145.

https://doi.org/10.1182/blood-2024-193210

Published: 2024

Journal Articles

Motixafortide for Hematopoietic Stem and Progenitor Cell Mobilization and Collection in Sickle Cell Disease

Alexis Kristine Leonard, Akshay Sharma, Yogindra Persaud, Parul Rai, Darla Pickett, Renee Massey, Neha Das Gupta, Subodh Selukar, Salem M. Akel, Leigh Poston, Yan Zheng, Ella Sorani, Irit Gliko Kabir, Mitchell J Weiss, Stephen Gottschalk, Julie Kanter, Matthew Hsieh, John Tisdale

Blood (2024) 144 (Supplement 1): 2100.1.

https://doi.org/10.1182/blood-2024-200330

Published: 2024

Journal Articles

Use of Combination Premedication Prior to Motixafortide Administration Reduced Severity and Frequency of AEs in the Phase 3 Genesis Trial - a Single Center Analysis

Zachary David Crees, Keith Stockerl-Goldstein, Mark A. Schroeder, Ravi Vij, Ella Sorani, Irit Gliko Kabir, Inbal Goldstein, Tzipi Lustig, Shaul Kadosh, John F. DiPersio

Blood (2023) 142 (Supplement 1): 3522.

https://doi.org/10.1182/blood-2023-181452

Published: 2023

Journal Articles

Prolonged CXCR4 Receptor Occupancy By Motixafortide Following a Single Subcutaneous Injection Is Associated with Extended Mobilization of CD34+ Cells in Peripheral Blood for > 24 Hours

Zachary David Crees, Keith Stockerl-Goldstein, Ella Sorani, Debby Ickowicz, Liron Darvish, John F. DiPersio

Blood (2023) 142 (Supplement 1): 5777.

https://doi.org/10.1182/blood-2023-184608

Published: 2023

Journal Articles

Double-Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of the High Affinity CXCR4 Inhibitor BL-8040 As Addition to Consolidation Therapy in AML By the SAL and OSHO Leukemia Study Groups

Sonia Jaramillo Segura, Maxi Wass, Judith Schaffrath, Kathrin Rieger, Axel Nogai, Mathias Haenel, Regina Herbst, Friedrich Stoelzel, Christoph Röllig, Edgar Jost, Richard F. Schlenk, Richard Noppeney, Christian H. Brandts, Utz Krug, Katharina S. Goetze, Sebastian Buske, Axel Florschütz, Jörg Schubert, Bernhard Opitz, Martin Mohren, Eva Eßeling, Stephan von Witzendorff, Marion Subklewe, Martin Kaufmann, Norbert Frickhofen, Christian W Scholz, Kerstin Schäfer-Eckart, Volker Kunzmann, Martin Schmidt-Hieber, Herbert G. Sayer, Andreas Rank, Philipp Hemmati, Frank Schueler, Simone Kowoll, Marina Scheller, Jörg Steighardt, Bayram Edemir, Lutz Peter Mueller, Irit Gliko-Kabir, Beatrice Ludwig-Kraus, Sabine Edemir, Ella Sorani, Mascha Binder, Abi Vainstein, Shaul Kadosh, Cora Gromann, Andreas Wienke, Claudia D. Baldus, Uwe Platzbecker, Hubert Serve, Martin Bornhaeuser, Christian Junghanss, Carsten Mueller-Tidow

Blood (2022) 140 (Supplement 1): 3338–3340.

https://doi.org/10.1182/blood-2022-166748

Published: 2022

Journal Articles

A Phase I Safety and Feasibility Study to Evaluate Motixafortide (CXCR4/SDF-1 Inhibition) and Natalizumab (VLA-4/VCAM-1 Inhibition) As a Novel Regimen to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapy in Sickle Cell Disease

Zachary D. Crees, Michael P. Rettig, Reyka G. Jayasinghe, Peter Ruminski, Abi Vainstein, Ella Sorani, Allison A. King, John F. DiPersio

Blood (2022) 140 (Supplement 1): 10432–10433.

https://doi.org/10.1182/blood-2022-165454

Published: 2022

Journal Articles

Immunophenotypic and Single-Cell Transcriptional Profiling of CD34+ Hematopoietic Stem and Progenitor Cells Mobilized with Motixafortide (BL-8040) and G-CSF Versus Plerixafor and G-CSF Versus Placebo and G-CSF: A Correlative Study of the Genesis Trial

Zachary D. Crees, Michael Retting, Reyka G Jayasinghe, Keith E. Stockerl-Goldstein, Abi Vainstein, Ella Sorani, Debby Ickowicz, Liron Shemesh-Darvish, Shaul Kadosh, John F. DiPersio

Blood (2021) 138 (Supplement 1): 3816.

https://doi.org/10.1182/blood-2021-144297

Published: 2021

Journal Articles

Motixafortide (BL-8040) and G-CSF Versus Placebo and G-CSF to Mobilize Hematopoietic Stem Cells for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: The Genesis Trial

Blood (2021) 138 (Supplement 1): 475.

https://doi.org/10.1182/blood-2021-144296

Published: 2021

Journal Articles

Hematopoietic Cell Transplantation of Higher CD34+ Cell Doses and Specific CD34+ Subsets Mobilized with Motixafortide and/or G-CSF Is Associated with Rapid Engraftment - a Post-Hoc Analysis of the Genesis Trial

Blood (2021) 138 (Supplement 1): 2849.

https://doi.org/10.1182/blood-2021-146783

Published: 2021

Journal Articles

The High Affinity CXCR4 Inhibitor, BL-8040, Impairs the Infiltration, Migration, Viability, and Differentiation of Regulatory T Cells

Michal Abraham, Inbal Mishalian, Abi Vainstein, Liron Shemesh-Darvish, Ella Sorani, Orly Eizenberg, Amnon Peled

Blood (2021) 138 (Supplement 1): 2804.

https://doi.org/10.1182/blood-2021-147142

Published: 2021

Journal Articles

Combined Inhibition of CXCR4 Signaling and System x c - Transporter Activity Induces Synthetic Lethality in T-ALL Cells By Suppressing Gsh and Inducing Ferroptosis

Jun Xia, PhD, Stephanie Sun, Matthew RM Jotte, Geoffrey L Uy, MD, Ella Sorani, PhD, Abi Vainstein, Liron Shemesh Davish, Katherine E Caldwell, William G Hawkins, Daniel C. Link, MD

Blood (2020) 136 (Supplement 1): 37.

https://doi.org/10.1182/blood-2020-142735

Published: 2020

Journal Articles

CXCR4 Inhibition with BL-8040 in Combination with Nelarabine in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia / Lymphoblastic Lymphoma

Geoffrey L. Uy, MD, Tapan M. Kadia, MD, Wendy Stock, MD, Jonathan E Brammer, MD, Osnat Bohana-Kashtan, PhD, Abi Vainstein, Ella Sorani, PhD, Hemda Chen, PharmD, John F. DiPersio, MD PhD, Daniel C. Link, MD

Blood (2019) 134 (Supplement_1): 2630.

https://doi.org/10.1182/blood-2019-127121

Published: 2019

Journal Articles

CXCR4 Blockade By BL-8040 in T Cell Acute Lymphoblastic Leukemia Decreases Mitochondrial Mass and Induces Non-Apoptotic Cell Death

Jun Xia, PhD, Stephanie Sun, Matthew RM Jotte, Geoffrey L. Uy, MD, Osnat Bohana-Kashtan, PhD, Ella Sorani, PhD, Abi Vainstein, Amnon Peled, PhD, Daniel C. Link, MD

Blood (2019) 134 (Supplement_1): 2745.

https://doi.org/10.1182/blood-2019-128881

Published: 2019

Journal Articles

The CXCR4 Antagonist, BL8040, Is Highly Active Against Human T-ALL in Preclinical Models

Jun Xia, PhD, Matthew RM Jotte, Stephanie Sun, Geoffrey L. Uy, MD, Abi Vainstein, Ella Sorani, PhD, Osnat Bohana-Kashtan, PhD, Stephen Shaw, PhD, Daniel C. Link, MD

Blood (2018) 132 (Supplement 1): 2700.

https://doi.org/10.1182/blood-2018-99-117213

Published: 2018

Journal Articles

Phase II Study Evaluating the Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem and Progenitor Cells for Allogeneic Hematopoietic Cell Transplantation and Phenotypic Characterization of the Leukapheresis Product

Michael P. Rettig, PhD, Geoffrey L. Uy, MD, Asad Bashey, MD PhD, Steven Devine, Samantha Jaglowski, MDMPH, Abi Vainstein, MD, Ella Sorani, PhD, Hemda Chen, PharmD, Osnat Bohana-Kashtan, PhD, Stephen Shaw, PhD, Peter Westervelt, MDPhD, John F. DiPersio, MD PhD

Blood (2018) 132 (Supplement 1): 118.

https://doi.org/10.1182/blood-2018-99-109701

Published: 2018

NARROW

Clonal Dynamics of Leukemic and Clonal Hematopoiesis Mutations Predict Relapse in Single Cell MRD Analysis of AML in First Complete Remission

Motixafortide (CXCR4 Inhibition) Alone and in Combination with Natalizumab (VLA-4 Inhibition) As a Novel Regimen to Mobilize Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease: A First-in-Human, Proof-of-Principle Safety and Feasibility Study

Motixafortide for Hematopoietic Stem and Progenitor Cell Mobilization and Collection in Sickle Cell Disease

Use of Combination Premedication Prior to Motixafortide Administration Reduced Severity and Frequency of AEs in the Phase 3 Genesis Trial - a Single Center Analysis

Prolonged CXCR4 Receptor Occupancy By Motixafortide Following a Single Subcutaneous Injection Is Associated with Extended Mobilization of CD34+ Cells in Peripheral Blood for > 24 Hours

Double-Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of the High Affinity CXCR4 Inhibitor BL-8040 As Addition to Consolidation Therapy in AML By the SAL and OSHO Leukemia Study Groups

A Phase I Safety and Feasibility Study to Evaluate Motixafortide (CXCR4/SDF-1 Inhibition) and Natalizumab (VLA-4/VCAM-1 Inhibition) As a Novel Regimen to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapy in Sickle Cell Disease

Immunophenotypic and Single-Cell Transcriptional Profiling of CD34+ Hematopoietic Stem and Progenitor Cells Mobilized with Motixafortide (BL-8040) and G-CSF Versus Plerixafor and G-CSF Versus Placebo and G-CSF: A Correlative Study of the Genesis Trial

Motixafortide (BL-8040) and G-CSF Versus Placebo and G-CSF to Mobilize Hematopoietic Stem Cells for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: The Genesis Trial

Hematopoietic Cell Transplantation of Higher CD34+ Cell Doses and Specific CD34+ Subsets Mobilized with Motixafortide and/or G-CSF Is Associated with Rapid Engraftment - a Post-Hoc Analysis of the Genesis Trial

The High Affinity CXCR4 Inhibitor, BL-8040, Impairs the Infiltration, Migration, Viability, and Differentiation of Regulatory T Cells

Combined Inhibition of CXCR4 Signaling and System x c - Transporter Activity Induces Synthetic Lethality in T-ALL Cells By Suppressing Gsh and Inducing Ferroptosis

CXCR4 Inhibition with BL-8040 in Combination with Nelarabine in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia / Lymphoblastic Lymphoma

CXCR4 Blockade By BL-8040 in T Cell Acute Lymphoblastic Leukemia Decreases Mitochondrial Mass and Induces Non-Apoptotic Cell Death

The CXCR4 Antagonist, BL8040, Is Highly Active Against Human T-ALL in Preclinical Models

Phase II Study Evaluating the Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem and Progenitor Cells for Allogeneic Hematopoietic Cell Transplantation and Phenotypic Characterization of the Leukapheresis Product

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only